Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

about

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

Item

http://www.wikidata.org/entity/Q58749448

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

@en

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

@nl

type

Item

label

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

@en

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

@nl

prefLabel

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

@en

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

@nl

P1476

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework

@en

P2093

Anja Oštrbenk

http://www.w3.org/2001/XMLSchema#string

Elizaveta Padalko

http://www.w3.org/2001/XMLSchema#string

Marc Arbyn

http://www.w3.org/2001/XMLSchema#string

P2860

European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document

The Measurement of Observer Agreement for Categorical Data

Note on the sampling error of the difference between correlated proportions or percentages

A review of human carcinogens--Part B: biological agents

Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.

Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus

HPV screening for cervical cancer in rural India.

Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.

P304

2704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJMS19092704

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mario Poljak

Lan Xu

P577

2018-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30208597

http://www.w3.org/2001/XMLSchema#string

P921

molecular biology

catalysis

P932

6165258

http://www.w3.org/2001/XMLSchema#string